Fierce Pharma Biopharma News & Insights
WEB2 days ago · Fierce Pharma delivers breaking news and analysis about drug companies, the FDA and the broader pharma industry, including manufacturing, marketing and finance.
GSK touts 3-year data on RSV shot Arexvy after CDC's narrower …
WEB11 hours ago · GSK on Tuesday unveiled fresh data from the late-stage AReSVi-006 study of Arexvy in older adults over the span of three full RSV seasons. In the trial, which looked at Arexvy’s ability to stop ...
Zealand, Boehringer win FDA breakthrough status to treat fatty …
WEB20 hours ago · The logo of German pharmaceutical company Boehringer Ingelheim is seen at its building in Shanghai, China February 1, 2019. Picture taken February 1, 2019.
Health & Pharma News | Latest Healthcare Stories | Reuters
WEB6 days ago · Find latest healthcare news from every corner of the globe at Reuters.com, your online source for breaking international news coverage.
Pharmaceuticals sector - Financial Times
WEBSep 26, 2024 · Comprehensive coverage of the pharmaceuticals industry. The latest news and developments from the world's leading drug companies, including Pfizer, Johnson & Johnson, AstraZeneca and more.
Pharma Industry - Latest News, Investigations and Analysis
WEB6 days ago · The latest news on health and wellness, including the healthcare industry, pharmaceuticals and more.
Top 10 most anticipated drug launches of 2024 | Fierce Pharma
WEBJan 29, 2024 · In two years, we’ve dropped more than $11 billion in sales potential as caution over new drug launches becomes a hardened trend. The top 10 list is based on Evaluate’s 2024 preview, where the ...
Biotech and Pharma Industry News | BioPharma Dive
WEBBioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
Top ten biopharma deals of 2024 - Nature
WEBMay 31, 2024 · Top ten biopharma deals of 2024. The first quarter of 2024 saw 115 agreed research and development partnerships totaling $36 billion. Eight of the top ten ranked by deal value involved technology...
Fresh from the biotech pipeline: record-breaking FDA approvals
WEBFeb 26, 2024 · Amgen’s tarlatamab could become the first delta-like ligand 3 (DLL3)-targeting bispecific T cell engager for small-cell lung cancer while Jazz Pharmaceuticals’ dual HER2 blocker zanidatamab ...